{"id":"https://openalex.org/W4409401038","doi":"https://doi.org/10.2147/dddt.s516394","title":"Comparative Analysis of Clinical Efficacy and Safety of Pyrotinib Plus Capecitabine versus Trastuzumab Emtansine (T-DM1) as Second-Line Treatment for HER2-Positive Advanced Breast Cancer: A Retrospective Study","display_name":"Comparative Analysis of Clinical Efficacy and Safety of Pyrotinib Plus Capecitabine versus Trastuzumab Emtansine (T-DM1) as Second-Line Treatment for HER2-Positive Advanced Breast Cancer: A Retrospective Study","publication_year":2025,"publication_date":"2025-04-01","ids":{"openalex":"https://openalex.org/W4409401038","doi":"https://doi.org/10.2147/dddt.s516394","pmid":"https://pubmed.ncbi.nlm.nih.gov/40255472"},"language":"en","primary_location":{"id":"doi:10.2147/dddt.s516394","doi":"https://doi.org/10.2147/dddt.s516394","is_oa":true,"landing_page_url":"https://doi.org/10.2147/dddt.s516394","pdf_url":null,"source":{"id":"https://openalex.org/S2496126384","display_name":"Drug Design Development and Therapy","issn_l":"1177-8881","issn":["1177-8881"],"is_oa":true,"is_in_doaj":true,"is_core":true,"listed_in":["cwts-core","doaj","dongbi-c","medline","norway-1","poland-70","russia-white-list-1","vabb-shw"],"host_organization":"https://openalex.org/P4310320348","host_organization_name":"Dove Medical Press","host_organization_lineage":["https://openalex.org/P4310320348","https://openalex.org/P4310320547"],"host_organization_lineage_names":["Dove Medical Press","Taylor & Francis"],"type":"journal"},"license":"cc-by-nc","license_id":"https://openalex.org/licenses/cc-by-nc","version":"publishedVersion","is_accepted":true,"is_published":true,"raw_source_name":"Drug Design, Development and Therapy","raw_type":"journal-article"},"volume":null,"type":"article","indexed_in":["crossref","doaj","pubmed"],"open_access":{"is_oa":true,"oa_status":"gold","oa_url":"https://doi.org/10.2147/dddt.s516394","any_repository_has_fulltext":true},"authorships":[{"author_position":"first","author":{"id":"https://openalex.org/A5103953806","display_name":"Hao Han","orcid":"https://orcid.org/0009-0007-0183-4321","observed_orcids":["https://orcid.org/0009-0007-0183-4321"]},"institutions":[],"countries":[],"is_corresponding":false,"raw_author_name":"Hao Han","raw_affiliation_strings":["Hospital of Shandong Second Medical University, School of Clinical Medicine, Shandong Second Medical University, Weifang, 261053, People's Republic of China"],"raw_orcid":"https://orcid.org/0009-0007-0183-4321","affiliations":[{"raw_affiliation_string":"Hospital of Shandong Second Medical University, School of Clinical Medicine, Shandong Second Medical University, Weifang, 261053, People's Republic of China","institution_ids":[]}]},{"author_position":"middle","author":{"id":"https://openalex.org/A5100358619","display_name":"Congcong Wang","orcid":"https://orcid.org/0000-0003-3947-2569","observed_orcids":["https://orcid.org/0000-0003-3947-2569"]},"institutions":[{"id":"https://openalex.org/I108688024","display_name":"Qingdao University","ror":"https://ror.org/021cj6z65","country_code":"CN","type":"education","lineage":["https://openalex.org/I108688024"]},{"id":"https://openalex.org/I3018397418","display_name":"Yuhuangding Hospital","ror":"https://ror.org/05vawe413","country_code":"CN","type":"healthcare","lineage":["https://openalex.org/I3018397418"]}],"countries":["CN"],"is_corresponding":false,"raw_author_name":"Congcong Wang","raw_affiliation_strings":["Department of Oncology, The Affiliated Yantai Yuhuangding Hospital of Qingdao University, Yantai, 264000, People's Republic of China"],"raw_orcid":null,"affiliations":[{"raw_affiliation_string":"Department of Oncology, The Affiliated Yantai Yuhuangding Hospital of Qingdao University, Yantai, 264000, People's Republic of China","institution_ids":["https://openalex.org/I108688024","https://openalex.org/I3018397418"]}]},{"author_position":"middle","author":{"id":"https://openalex.org/A5038391766","display_name":"Fenge Jiang","orcid":null,"observed_orcids":[]},"institutions":[{"id":"https://openalex.org/I108688024","display_name":"Qingdao University","ror":"https://ror.org/021cj6z65","country_code":"CN","type":"education","lineage":["https://openalex.org/I108688024"]},{"id":"https://openalex.org/I3018397418","display_name":"Yuhuangding Hospital","ror":"https://ror.org/05vawe413","country_code":"CN","type":"healthcare","lineage":["https://openalex.org/I3018397418"]}],"countries":["CN"],"is_corresponding":false,"raw_author_name":"Fenge Jiang","raw_affiliation_strings":["Department of Oncology, The Affiliated Yantai Yuhuangding Hospital of Qingdao University, Yantai, 264000, People's Republic of China"],"raw_orcid":null,"affiliations":[{"raw_affiliation_string":"Department of Oncology, The Affiliated Yantai Yuhuangding Hospital of Qingdao University, Yantai, 264000, People's Republic of China","institution_ids":["https://openalex.org/I108688024","https://openalex.org/I3018397418"]}]},{"author_position":"middle","author":{"id":"https://openalex.org/A5100642451","display_name":"Ping Sun","orcid":"https://orcid.org/0000-0002-2127-7207","observed_orcids":["https://orcid.org/0000-0002-2127-7207"]},"institutions":[{"id":"https://openalex.org/I108688024","display_name":"Qingdao University","ror":"https://ror.org/021cj6z65","country_code":"CN","type":"education","lineage":["https://openalex.org/I108688024"]},{"id":"https://openalex.org/I3018397418","display_name":"Yuhuangding Hospital","ror":"https://ror.org/05vawe413","country_code":"CN","type":"healthcare","lineage":["https://openalex.org/I3018397418"]}],"countries":["CN"],"is_corresponding":false,"raw_author_name":"Ping Sun","raw_affiliation_strings":["Department of Oncology, The Affiliated Yantai Yuhuangding Hospital of Qingdao University, Yantai, 264000, People's Republic of China"],"raw_orcid":null,"affiliations":[{"raw_affiliation_string":"Department of Oncology, The Affiliated Yantai Yuhuangding Hospital of Qingdao University, Yantai, 264000, People's Republic of China","institution_ids":["https://openalex.org/I108688024","https://openalex.org/I3018397418"]}]},{"author_position":"last","author":{"id":"https://openalex.org/A5111477112","display_name":"Jiannan Liu","orcid":"https://orcid.org/0000-0003-4503-5349","observed_orcids":["https://orcid.org/0000-0003-4503-5349"]},"institutions":[{"id":"https://openalex.org/I108688024","display_name":"Qingdao University","ror":"https://ror.org/021cj6z65","country_code":"CN","type":"education","lineage":["https://openalex.org/I108688024"]},{"id":"https://openalex.org/I3018397418","display_name":"Yuhuangding Hospital","ror":"https://ror.org/05vawe413","country_code":"CN","type":"healthcare","lineage":["https://openalex.org/I3018397418"]}],"countries":["CN"],"is_corresponding":false,"raw_author_name":"Jiannan Liu","raw_affiliation_strings":["Department of Oncology, The Affiliated Yantai Yuhuangding Hospital of Qingdao University, Yantai, 264000, People's Republic of China"],"raw_orcid":null,"affiliations":[{"raw_affiliation_string":"Department of Oncology, The Affiliated Yantai Yuhuangding Hospital of Qingdao University, Yantai, 264000, People's Republic of China","institution_ids":["https://openalex.org/I108688024","https://openalex.org/I3018397418"]}]}],"institutions":[],"countries_distinct_count":1,"institutions_distinct_count":2,"corresponding_author_ids":[],"corresponding_institution_ids":[],"apc_list":{"value":2836,"currency":"USD","value_usd":2836},"apc_paid":{"value":2836,"currency":"USD","value_usd":2836},"fwci":0.3605,"has_fulltext":true,"cited_by_count":1,"citation_normalized_percentile":{"value":0.56179032,"is_in_top_1_percent":false,"is_in_top_10_percent":false},"cited_by_percentile_year":{"min":90,"max":94},"biblio":{"volume":"Volume 19","issue":null,"first_page":"2885","last_page":"2895"},"is_retracted":false,"is_paratext":false,"is_xpac":false,"primary_topic":{"id":"https://openalex.org/T10755","display_name":"HER2/EGFR in Cancer Research","score":0.9955999851226807,"subfield":{"id":"https://openalex.org/subfields/2730","display_name":"Oncology"},"field":{"id":"https://openalex.org/fields/27","display_name":"Medicine"},"domain":{"id":"https://openalex.org/domains/4","display_name":"Health Sciences"}},"topics":[{"id":"https://openalex.org/T10755","display_name":"HER2/EGFR in Cancer Research","score":0.9955999851226807,"subfield":{"id":"https://openalex.org/subfields/2730","display_name":"Oncology"},"field":{"id":"https://openalex.org/fields/27","display_name":"Medicine"},"domain":{"id":"https://openalex.org/domains/4","display_name":"Health Sciences"}},{"id":"https://openalex.org/T10696","display_name":"Gastric Cancer Management and Outcomes","score":0.0010999999940395355,"subfield":{"id":"https://openalex.org/subfields/2740","display_name":"Pulmonary and Respiratory Medicine"},"field":{"id":"https://openalex.org/fields/27","display_name":"Medicine"},"domain":{"id":"https://openalex.org/domains/4","display_name":"Health Sciences"}},{"id":"https://openalex.org/T10417","display_name":"Lung Cancer Treatments and Mutations","score":0.0010000000474974513,"subfield":{"id":"https://openalex.org/subfields/2740","display_name":"Pulmonary and Respiratory Medicine"},"field":{"id":"https://openalex.org/fields/27","display_name":"Medicine"},"domain":{"id":"https://openalex.org/domains/4","display_name":"Health Sciences"}}],"keywords":[{"id":"https://openalex.org/keywords/her2-positive-breast-cancer","display_name":"HER2-positive breast cancer","score":0.7210000157356262},{"id":"https://openalex.org/keywords/pyrotinib","display_name":"pyrotinib","score":0.8140000104904175},{"id":"https://openalex.org/keywords/capecitabine","display_name":"capecitabine","score":0.9959999918937683},{"id":"https://openalex.org/keywords/trastuzumab-emtansine","display_name":"trastuzumab emtansine","score":0.9900000095367432},{"id":"https://openalex.org/keywords/second-line-treatment","display_name":"second-line therapy","score":0.824999988079071},{"id":"https://openalex.org/keywords/progression-free-survival","display_name":"progression-free survival","score":0.9539999961853027},{"id":"https://openalex.org/keywords/overall-survival","display_name":"overall survival","score":0.5889999866485596},{"id":"https://openalex.org/keywords/objective-response-rate","display_name":"objective response rate","score":0.8180000185966492},{"id":"https://openalex.org/keywords/disease-control-rate","display_name":"disease control rate","score":0.7799999713897705},{"id":"https://openalex.org/keywords/adverse-events","display_name":"adverse events","score":0.8460000157356262},{"id":"https://openalex.org/keywords/diarrhea","display_name":"diarrhea","score":0.8920000195503235},{"id":"https://openalex.org/keywords/thrombocytopenia","display_name":"thrombocytopenia","score":0.9980000257492065},{"id":"https://openalex.org/keywords/tyrosine-kinase-inhibitors","display_name":"tyrosine kinase inhibitors","score":0.6579999923706055},{"id":"https://openalex.org/keywords/antibody-drug-conjugates","display_name":"antibody-drug conjugates","score":0.9110000133514404}],"concepts":[{"id":"https://openalex.org/C2777909004","wikidata":"https://www.wikidata.org/wiki/Q420207","display_name":"Capecitabine","level":4,"score":0.9342963695526123},{"id":"https://openalex.org/C71924100","wikidata":"https://www.wikidata.org/wiki/Q11190","display_name":"Medicine","level":0,"score":0.7143007516860962},{"id":"https://openalex.org/C2778087150","wikidata":"https://www.wikidata.org/wiki/Q3997863","display_name":"Trastuzumab emtansine","level":5,"score":0.6865639686584473},{"id":"https://openalex.org/C2779786085","wikidata":"https://www.wikidata.org/wiki/Q412616","display_name":"Trastuzumab","level":4,"score":0.5967921018600464},{"id":"https://openalex.org/C143998085","wikidata":"https://www.wikidata.org/wiki/Q162555","display_name":"Oncology","level":1,"score":0.5690679550170898},{"id":"https://openalex.org/C126322002","wikidata":"https://www.wikidata.org/wiki/Q11180","display_name":"Internal medicine","level":1,"score":0.49770811200141907},{"id":"https://openalex.org/C530470458","wikidata":"https://www.wikidata.org/wiki/Q128581","display_name":"Breast cancer","level":3,"score":0.48898208141326904},{"id":"https://openalex.org/C167135981","wikidata":"https://www.wikidata.org/wiki/Q2146302","display_name":"Retrospective cohort study","level":2,"score":0.44405877590179443},{"id":"https://openalex.org/C121608353","wikidata":"https://www.wikidata.org/wiki/Q12078","display_name":"Cancer","level":2,"score":0.37770408391952515},{"id":"https://openalex.org/C526805850","wikidata":"https://www.wikidata.org/wiki/Q188874","display_name":"Colorectal cancer","level":3,"score":0.0}],"mesh":[{"descriptor_ui":"D000069287","descriptor_name":"Capecitabine","qualifier_ui":"Q000008","qualifier_name":"administration & dosage","is_major_topic":true},{"descriptor_ui":"D000069287","descriptor_name":"Capecitabine","qualifier_ui":"Q000008","qualifier_name":"administration & dosage","is_major_topic":true},{"descriptor_ui":"D000069287","descriptor_name":"Capecitabine","qualifier_ui":"Q000008","qualifier_name":"administration & dosage","is_major_topic":true},{"descriptor_ui":"D000069287","descriptor_name":"Capecitabine","qualifier_ui":"Q000009","qualifier_name":"adverse effects","is_major_topic":true},{"descriptor_ui":"D000069287","descriptor_name":"Capecitabine","qualifier_ui":"Q000009","qualifier_name":"adverse effects","is_major_topic":true},{"descriptor_ui":"D000069287","descriptor_name":"Capecitabine","qualifier_ui":"Q000009","qualifier_name":"adverse effects","is_major_topic":true},{"descriptor_ui":"D000069287","descriptor_name":"Capecitabine","qualifier_ui":"Q000494","qualifier_name":"pharmacology","is_major_topic":true},{"descriptor_ui":"D000069287","descriptor_name":"Capecitabine","qualifier_ui":"Q000494","qualifier_name":"pharmacology","is_major_topic":true},{"descriptor_ui":"D000069287","descriptor_name":"Capecitabine","qualifier_ui":"Q000494","qualifier_name":"pharmacology","is_major_topic":true},{"descriptor_ui":"D000069287","descriptor_name":"Capecitabine","qualifier_ui":"Q000627","qualifier_name":"therapeutic use","is_major_topic":true},{"descriptor_ui":"D000069287","descriptor_name":"Capecitabine","qualifier_ui":"Q000627","qualifier_name":"therapeutic use","is_major_topic":true},{"descriptor_ui":"D000069287","descriptor_name":"Capecitabine","qualifier_ui":"Q000627","qualifier_name":"therapeutic use","is_major_topic":true},{"descriptor_ui":"D000080044","descriptor_name":"Ado-Trastuzumab Emtansine","qualifier_ui":"Q000008","qualifier_name":"administration & dosage","is_major_topic":true},{"descriptor_ui":"D000080044","descriptor_name":"Ado-Trastuzumab Emtansine","qualifier_ui":"Q000008","qualifier_name":"administration & dosage","is_major_topic":true},{"descriptor_ui":"D000080044","descriptor_name":"Ado-Trastuzumab Emtansine","qualifier_ui":"Q000008","qualifier_name":"administration & dosage","is_major_topic":true},{"descriptor_ui":"D000080044","descriptor_name":"Ado-Trastuzumab Emtansine","qualifier_ui":"Q000009","qualifier_name":"adverse effects","is_major_topic":true},{"descriptor_ui":"D000080044","descriptor_name":"Ado-Trastuzumab Emtansine","qualifier_ui":"Q000009","qualifier_name":"adverse effects","is_major_topic":true},{"descriptor_ui":"D000080044","descriptor_name":"Ado-Trastuzumab Emtansine","qualifier_ui":"Q000009","qualifier_name":"adverse effects","is_major_topic":true},{"descriptor_ui":"D000080044","descriptor_name":"Ado-Trastuzumab Emtansine","qualifier_ui":"Q000494","qualifier_name":"pharmacology","is_major_topic":true},{"descriptor_ui":"D000080044","descriptor_name":"Ado-Trastuzumab Emtansine","qualifier_ui":"Q000494","qualifier_name":"pharmacology","is_major_topic":true},{"descriptor_ui":"D000080044","descriptor_name":"Ado-Trastuzumab Emtansine","qualifier_ui":"Q000494","qualifier_name":"pharmacology","is_major_topic":true},{"descriptor_ui":"D000080044","descriptor_name":"Ado-Trastuzumab Emtansine","qualifier_ui":"Q000627","qualifier_name":"therapeutic use","is_major_topic":true},{"descriptor_ui":"D000080044","descriptor_name":"Ado-Trastuzumab Emtansine","qualifier_ui":"Q000627","qualifier_name":"therapeutic use","is_major_topic":true},{"descriptor_ui":"D000080044","descriptor_name":"Ado-Trastuzumab Emtansine","qualifier_ui":"Q000627","qualifier_name":"therapeutic use","is_major_topic":true},{"descriptor_ui":"D000178","descriptor_name":"Acrylamides","qualifier_ui":"Q000008","qualifier_name":"administration & dosage","is_major_topic":true},{"descriptor_ui":"D000178","descriptor_name":"Acrylamides","qualifier_ui":"Q000008","qualifier_name":"administration & dosage","is_major_topic":true},{"descriptor_ui":"D000178","descriptor_name":"Acrylamides","qualifier_ui":"Q000008","qualifier_name":"administration & dosage","is_major_topic":true},{"descriptor_ui":"D000178","descriptor_name":"Acrylamides","qualifier_ui":"Q000009","qualifier_name":"adverse effects","is_major_topic":true},{"descriptor_ui":"D000178","descriptor_name":"Acrylamides","qualifier_ui":"Q000009","qualifier_name":"adverse effects","is_major_topic":true},{"descriptor_ui":"D000178","descriptor_name":"Acrylamides","qualifier_ui":"Q000009","qualifier_name":"adverse effects","is_major_topic":true},{"descriptor_ui":"D000178","descriptor_name":"Acrylamides","qualifier_ui":"Q000494","qualifier_name":"pharmacology","is_major_topic":true},{"descriptor_ui":"D000178","descriptor_name":"Acrylamides","qualifier_ui":"Q000494","qualifier_name":"pharmacology","is_major_topic":true},{"descriptor_ui":"D000178","descriptor_name":"Acrylamides","qualifier_ui":"Q000494","qualifier_name":"pharmacology","is_major_topic":true},{"descriptor_ui":"D000178","descriptor_name":"Acrylamides","qualifier_ui":"Q000627","qualifier_name":"therapeutic use","is_major_topic":true},{"descriptor_ui":"D000178","descriptor_name":"Acrylamides","qualifier_ui":"Q000627","qualifier_name":"therapeutic use","is_major_topic":true},{"descriptor_ui":"D000178","descriptor_name":"Acrylamides","qualifier_ui":"Q000627","qualifier_name":"therapeutic use","is_major_topic":true},{"descriptor_ui":"D000328","descriptor_name":"Adult","qualifier_ui":null,"qualifier_name":null,"is_major_topic":false},{"descriptor_ui":"D000328","descriptor_name":"Adult","qualifier_ui":null,"qualifier_name":null,"is_major_topic":false},{"descriptor_ui":"D000328","descriptor_name":"Adult","qualifier_ui":null,"qualifier_name":null,"is_major_topic":false},{"descriptor_ui":"D000368","descriptor_name":"Aged","qualifier_ui":null,"qualifier_name":null,"is_major_topic":false},{"descriptor_ui":"D000368","descriptor_name":"Aged","qualifier_ui":null,"qualifier_name":null,"is_major_topic":false},{"descriptor_ui":"D000368","descriptor_name":"Aged","qualifier_ui":null,"qualifier_name":null,"is_major_topic":false},{"descriptor_ui":"D000634","descriptor_name":"Aminoquinolines","qualifier_ui":"Q000008","qualifier_name":"administration & dosage","is_major_topic":true},{"descriptor_ui":"D000634","descriptor_name":"Aminoquinolines","qualifier_ui":"Q000008","qualifier_name":"administration & dosage","is_major_topic":true},{"descriptor_ui":"D000634","descriptor_name":"Aminoquinolines","qualifier_ui":"Q000008","qualifier_name":"administration & dosage","is_major_topic":true},{"descriptor_ui":"D000634","descriptor_name":"Aminoquinolines","qualifier_ui":"Q000009","qualifier_name":"adverse effects","is_major_topic":true},{"descriptor_ui":"D000634","descriptor_name":"Aminoquinolines","qualifier_ui":"Q000009","qualifier_name":"adverse effects","is_major_topic":true},{"descriptor_ui":"D000634","descriptor_name":"Aminoquinolines","qualifier_ui":"Q000009","qualifier_name":"adverse effects","is_major_topic":true},{"descriptor_ui":"D000634","descriptor_name":"Aminoquinolines","qualifier_ui":"Q000494","qualifier_name":"pharmacology","is_major_topic":true},{"descriptor_ui":"D000634","descriptor_name":"Aminoquinolines","qualifier_ui":"Q000494","qualifier_name":"pharmacology","is_major_topic":true},{"descriptor_ui":"D000634","descriptor_name":"Aminoquinolines","qualifier_ui":"Q000494","qualifier_name":"pharmacology","is_major_topic":true},{"descriptor_ui":"D000971","descriptor_name":"Antineoplastic Combined Chemotherapy Protocols","qualifier_ui":"Q000008","qualifier_name":"administration & dosage","is_major_topic":true},{"descriptor_ui":"D000971","descriptor_name":"Antineoplastic Combined Chemotherapy Protocols","qualifier_ui":"Q000008","qualifier_name":"administration & dosage","is_major_topic":true},{"descriptor_ui":"D000971","descriptor_name":"Antineoplastic Combined Chemotherapy Protocols","qualifier_ui":"Q000008","qualifier_name":"administration & dosage","is_major_topic":true},{"descriptor_ui":"D000971","descriptor_name":"Antineoplastic Combined Chemotherapy Protocols","qualifier_ui":"Q000009","qualifier_name":"adverse effects","is_major_topic":true},{"descriptor_ui":"D000971","descriptor_name":"Antineoplastic Combined Chemotherapy Protocols","qualifier_ui":"Q000009","qualifier_name":"adverse effects","is_major_topic":true},{"descriptor_ui":"D000971","descriptor_name":"Antineoplastic Combined Chemotherapy Protocols","qualifier_ui":"Q000009","qualifier_name":"adverse effects","is_major_topic":true},{"descriptor_ui":"D000971","descriptor_name":"Antineoplastic Combined Chemotherapy Protocols","qualifier_ui":"Q000494","qualifier_name":"pharmacology","is_major_topic":true},{"descriptor_ui":"D000971","descriptor_name":"Antineoplastic Combined Chemotherapy Protocols","qualifier_ui":"Q000494","qualifier_name":"pharmacology","is_major_topic":true},{"descriptor_ui":"D000971","descriptor_name":"Antineoplastic Combined Chemotherapy Protocols","qualifier_ui":"Q000494","qualifier_name":"pharmacology","is_major_topic":true},{"descriptor_ui":"D000971","descriptor_name":"Antineoplastic Combined Chemotherapy Protocols","qualifier_ui":"Q000627","qualifier_name":"therapeutic use","is_major_topic":true},{"descriptor_ui":"D000971","descriptor_name":"Antineoplastic Combined Chemotherapy Protocols","qualifier_ui":"Q000627","qualifier_name":"therapeutic use","is_major_topic":true},{"descriptor_ui":"D000971","descriptor_name":"Antineoplastic Combined Chemotherapy Protocols","qualifier_ui":"Q000627","qualifier_name":"therapeutic use","is_major_topic":true},{"descriptor_ui":"D001943","descriptor_name":"Breast Neoplasms","qualifier_ui":"Q000188","qualifier_name":"drug therapy","is_major_topic":true},{"descriptor_ui":"D001943","descriptor_name":"Breast Neoplasms","qualifier_ui":"Q000188","qualifier_name":"drug therapy","is_major_topic":true},{"descriptor_ui":"D001943","descriptor_name":"Breast Neoplasms","qualifier_ui":"Q000188","qualifier_name":"drug therapy","is_major_topic":true},{"descriptor_ui":"D001943","descriptor_name":"Breast Neoplasms","qualifier_ui":"Q000378","qualifier_name":"metabolism","is_major_topic":true},{"descriptor_ui":"D001943","descriptor_name":"Breast Neoplasms","qualifier_ui":"Q000378","qualifier_name":"metabolism","is_major_topic":true},{"descriptor_ui":"D001943","descriptor_name":"Breast Neoplasms","qualifier_ui":"Q000378","qualifier_name":"metabolism","is_major_topic":true},{"descriptor_ui":"D001943","descriptor_name":"Breast Neoplasms","qualifier_ui":"Q000473","qualifier_name":"pathology","is_major_topic":true},{"descriptor_ui":"D001943","descriptor_name":"Breast Neoplasms","qualifier_ui":"Q000473","qualifier_name":"pathology","is_major_topic":true},{"descriptor_ui":"D001943","descriptor_name":"Breast Neoplasms","qualifier_ui":"Q000473","qualifier_name":"pathology","is_major_topic":true},{"descriptor_ui":"D005260","descriptor_name":"Female","qualifier_ui":null,"qualifier_name":null,"is_major_topic":false},{"descriptor_ui":"D005260","descriptor_name":"Female","qualifier_ui":null,"qualifier_name":null,"is_major_topic":false},{"descriptor_ui":"D005260","descriptor_name":"Female","qualifier_ui":null,"qualifier_name":null,"is_major_topic":false},{"descriptor_ui":"D006801","descriptor_name":"Humans","qualifier_ui":null,"qualifier_name":null,"is_major_topic":false},{"descriptor_ui":"D006801","descriptor_name":"Humans","qualifier_ui":null,"qualifier_name":null,"is_major_topic":false},{"descriptor_ui":"D006801","descriptor_name":"Humans","qualifier_ui":null,"qualifier_name":null,"is_major_topic":false},{"descriptor_ui":"D008875","descriptor_name":"Middle Aged","qualifier_ui":null,"qualifier_name":null,"is_major_topic":false},{"descriptor_ui":"D008875","descriptor_name":"Middle Aged","qualifier_ui":null,"qualifier_name":null,"is_major_topic":false},{"descriptor_ui":"D008875","descriptor_name":"Middle Aged","qualifier_ui":null,"qualifier_name":null,"is_major_topic":false},{"descriptor_ui":"D012189","descriptor_name":"Retrospective Studies","qualifier_ui":null,"qualifier_name":null,"is_major_topic":false},{"descriptor_ui":"D012189","descriptor_name":"Retrospective Studies","qualifier_ui":null,"qualifier_name":null,"is_major_topic":false},{"descriptor_ui":"D012189","descriptor_name":"Retrospective Studies","qualifier_ui":null,"qualifier_name":null,"is_major_topic":false},{"descriptor_ui":"D016896","descriptor_name":"Treatment Outcome","qualifier_ui":null,"qualifier_name":null,"is_major_topic":false},{"descriptor_ui":"D016896","descriptor_name":"Treatment Outcome","qualifier_ui":null,"qualifier_name":null,"is_major_topic":false},{"descriptor_ui":"D016896","descriptor_name":"Treatment Outcome","qualifier_ui":null,"qualifier_name":null,"is_major_topic":false},{"descriptor_ui":"D018719","descriptor_name":"Receptor, ErbB-2","qualifier_ui":"Q000037","qualifier_name":"antagonists & inhibitors","is_major_topic":true},{"descriptor_ui":"D018719","descriptor_name":"Erb-b2 Receptor Tyrosine Kinases","qualifier_ui":"Q000037","qualifier_name":"antagonists & inhibitors","is_major_topic":true},{"descriptor_ui":"D018719","descriptor_name":"Receptor, ErbB-2","qualifier_ui":"Q000037","qualifier_name":"antagonists & inhibitors","is_major_topic":true},{"descriptor_ui":"D018719","descriptor_name":"Receptor, ErbB-2","qualifier_ui":"Q000378","qualifier_name":"metabolism","is_major_topic":true},{"descriptor_ui":"D018719","descriptor_name":"Erb-b2 Receptor Tyrosine Kinases","qualifier_ui":"Q000378","qualifier_name":"metabolism","is_major_topic":true},{"descriptor_ui":"D018719","descriptor_name":"Receptor, ErbB-2","qualifier_ui":"Q000378","qualifier_name":"metabolism","is_major_topic":true}],"locations_count":4,"locations":[{"id":"doi:10.2147/dddt.s516394","doi":"https://doi.org/10.2147/dddt.s516394","is_oa":true,"landing_page_url":"https://doi.org/10.2147/dddt.s516394","pdf_url":null,"source":{"id":"https://openalex.org/S2496126384","display_name":"Drug Design Development and Therapy","issn_l":"1177-8881","issn":["1177-8881"],"is_oa":true,"is_in_doaj":true,"is_core":true,"listed_in":["cwts-core","doaj","dongbi-c","medline","norway-1","poland-70","russia-white-list-1","vabb-shw"],"host_organization":"https://openalex.org/P4310320348","host_organization_name":"Dove Medical Press","host_organization_lineage":["https://openalex.org/P4310320348","https://openalex.org/P4310320547"],"host_organization_lineage_names":["Dove Medical Press","Taylor & Francis"],"type":"journal"},"license":"cc-by-nc","license_id":"https://openalex.org/licenses/cc-by-nc","version":"publishedVersion","is_accepted":true,"is_published":true,"raw_source_name":"Drug Design, Development and Therapy","raw_type":"journal-article"},{"id":"pmid:40255472","doi":null,"is_oa":false,"landing_page_url":"https://pubmed.ncbi.nlm.nih.gov/40255472","pdf_url":null,"source":{"id":"https://openalex.org/S4306525036","display_name":"PubMed","issn_l":null,"issn":null,"is_oa":false,"is_in_doaj":false,"is_core":false,"listed_in":[],"host_organization":"https://openalex.org/I1299303238","host_organization_name":"National Institutes of Health","host_organization_lineage":["https://openalex.org/I1299303238"],"host_organization_lineage_names":[],"type":"repository"},"license":null,"license_id":null,"version":"publishedVersion","is_accepted":true,"is_published":true,"raw_source_name":"Drug design, development and therapy","raw_type":"Journal Article"},{"id":"pmh:oai:dovepress.com/102069","doi":null,"is_oa":true,"landing_page_url":"https://www.dovepress.com/comparative-analysis-of-clinical-efficacy-and-safety-of-pyrotinib-plus-peer-reviewed-fulltext-article-DDDT","pdf_url":"https://www.dovepress.com/article/download/102069","source":{"id":"https://openalex.org/S4306401012","display_name":"Dove Medical Press (Taylor and Francis Group)","issn_l":null,"issn":null,"is_oa":false,"is_in_doaj":false,"is_core":false,"listed_in":[],"host_organization":null,"host_organization_name":null,"host_organization_lineage":[],"host_organization_lineage_names":[],"type":"repository"},"license":"cc-by-nc","license_id":"https://openalex.org/licenses/cc-by-nc","version":"submittedVersion","is_accepted":false,"is_published":false,"raw_source_name":null,"raw_type":"info:eu-repo/semantics/article"},{"id":"pmh:oai:pubmedcentral.nih.gov:12007508","doi":null,"is_oa":true,"landing_page_url":"https://www.ncbi.nlm.nih.gov/pmc/articles/12007508","pdf_url":null,"source":{"id":"https://openalex.org/S2764455111","display_name":"PubMed Central","issn_l":null,"issn":null,"is_oa":true,"is_in_doaj":false,"is_core":false,"listed_in":[],"host_organization":"https://openalex.org/I1299303238","host_organization_name":"National Institutes of Health","host_organization_lineage":["https://openalex.org/I1299303238"],"host_organization_lineage_names":[],"type":"repository"},"license":"cc-by-nc","license_id":"https://openalex.org/licenses/cc-by-nc","version":"submittedVersion","is_accepted":false,"is_published":false,"raw_source_name":"Drug Des Devel Ther","raw_type":"Text"}],"best_oa_location":{"id":"doi:10.2147/dddt.s516394","doi":"https://doi.org/10.2147/dddt.s516394","is_oa":true,"landing_page_url":"https://doi.org/10.2147/dddt.s516394","pdf_url":null,"source":{"id":"https://openalex.org/S2496126384","display_name":"Drug Design Development and Therapy","issn_l":"1177-8881","issn":["1177-8881"],"is_oa":true,"is_in_doaj":true,"is_core":true,"listed_in":["cwts-core","doaj","dongbi-c","medline","norway-1","poland-70","russia-white-list-1","vabb-shw"],"host_organization":"https://openalex.org/P4310320348","host_organization_name":"Dove Medical Press","host_organization_lineage":["https://openalex.org/P4310320348","https://openalex.org/P4310320547"],"host_organization_lineage_names":["Dove Medical Press","Taylor & Francis"],"type":"journal"},"license":"cc-by-nc","license_id":"https://openalex.org/licenses/cc-by-nc","version":"publishedVersion","is_accepted":true,"is_published":true,"raw_source_name":"Drug Design, Development and Therapy","raw_type":"journal-article"},"sustainable_development_goals":[{"score":1.0,"id":"https://metadata.un.org/sdg/3","display_name":"Good health and well-being"}],"sustainable_development_goals_aurora":[{"score":0.7599999904632568,"id":"https://metadata.un.org/sdg/3","display_name":"Good health and well-being"}],"study_designs":[{"id":"https://openalex.org/study-designs/observational-study","display_name":"Observational Study"}],"awards":[{"id":"https://openalex.org/G7245220998","display_name":null,"funder_award_id":"82103585","funder_id":"https://openalex.org/F4320321001","funder_display_name":"National Natural Science Foundation of China"}],"funders":[{"id":"https://openalex.org/F4320321001","display_name":"National Natural Science Foundation of China","ror":"https://ror.org/01h0zpd94"}],"has_content":{"grobid_xml":false,"pdf":false},"content_urls":null,"referenced_works_count":0,"referenced_works":[],"related_works":["https://openalex.org/W4391375266","https://openalex.org/W3144346200","https://openalex.org/W2407798196","https://openalex.org/W2409395100","https://openalex.org/W2184399937","https://openalex.org/W2592350521","https://openalex.org/W3006658735","https://openalex.org/W1594988246","https://openalex.org/W2901986589","https://openalex.org/W1968590850"],"abstract_inverted_index":{"Background:":[0],"HER2-positive":[1,280],"advanced":[2,281],"breast":[3,67,282,294],"cancer":[4,68],"poses":[5],"significant":[6],"treatment":[7],"challenges.":[8],"In":[9],"China,":[10],"T-DM1":[11,52,99,176,225,276],"and":[12,25,37,49,75,152,186,200,222],"pyrotinib":[13,54,112,169,185,192,217],"are":[14,59],"key":[15],"second-line":[16],"therapies.":[17],"A":[18],"comprehensive":[19],"evaluation":[20],"of":[21,28,51,129],"the":[22,46,81,90,106,137,157,168,175,210,216,224,234,254],"comparative":[23],"efficacy":[24,48,287],"safety":[26,50,291],"profiles":[27],"these":[29],"therapies":[30],"is":[31],"imperative":[32],"for":[33,167,174,184,189],"optimizing":[34],"therapeutic":[35],"strategies":[36],"enhancing":[38],"patient":[39],"outcomes.":[40,159],"This":[41,83],"study":[42,84],"aims":[43],"to":[44,250,275],"compare":[45],"clinical":[47],"against":[53],"plus":[55,117,268],"capecitabine.":[56],"Methods:":[57],"Patients":[58],"females":[60],"with":[61,279],"HER2-positive,":[62],"locally":[63],"advanced,":[64],"or":[65,237],"metastatic":[66],"who":[69,88],"at":[70,247],"least":[71],"18":[72],"years":[73],"old":[74],"have":[76],"received":[77,97],"anti-HER2":[78],"therapy":[79],"in":[80,215,223,277],"past.":[82],"included":[85],"148":[86],"patients":[87,96,109,278],"satisfied":[89],"inclusion":[91],"criteria.":[92],"Of":[93],"these,":[94],"74":[95,108],"intravenous":[98],"(3.6":[100],"mg/kg)":[101],"every":[102],"21":[103],"days,":[104],"while":[105,140],"other":[107],"got":[110],"oral":[111],"(400":[113],"mg,":[114],"once":[115],"daily)":[116],"capecitabine":[118,269],"(1000":[119],"mg/m":[120],"2":[121],",":[122],"twice":[123],"daily":[124],"on":[125],"days":[126],"1\u2013":[127],"14":[128],"each":[130],"21-day":[131],"cycle).":[132],"Progression-free":[133],"survival":[134,142],"(PFS)":[135],"was":[136,164,181,219,228],"main":[138],"outcome,":[139],"overall":[141],"(OS),":[143],"objective":[144],"response":[145],"rate":[146,150],"(ORR),":[147],"disease":[148],"control":[149],"(DCR),":[151],"adverse":[153,206,242,255,263],"events":[154,207,243,256],"(AEs)":[155],"were":[156,208,257],"secondary":[158],"Results:":[160],"The":[161,178,191],"median":[162,179,272],"PFS":[163,273],"12.2":[165],"months":[166,173,183,188],"group":[170,193,218,260],"vs":[171,198,203],"9.1":[172],"group.":[177],"follow-up":[180],"12.7":[182],"9.3":[187],"T-DM1.":[190],"had":[194],"better":[195],"DCR":[196],"(56.8%":[197],"54.1%)":[199],"ORR":[201],"(40.5%":[202],"29.7%).":[204],"While":[205],"manageable,":[209],"most":[211,241],"common":[212],"severe":[213],"AE":[214],"diarrhea":[220],"(24.3%),":[221],"group,":[226],"it":[227],"thrombocytopenia":[229],"(16.2%).":[230],"However,":[231],"by":[232],"reducing":[233],"drug":[235],"dosage":[236],"providing":[238],"symptomatic":[239],"treatment,":[240],"could":[244],"be":[245],"controlled":[246],"grades":[248],"1":[249],"2,":[251],"indicating":[252],"that":[253],"manageable.":[258],"Neither":[259],"recorded":[261],"any":[262],"event-related":[264],"deaths.":[265],"Conclusion:":[266],"Pyrotinib":[267],"significantly":[270],"improves":[271],"compared":[274],"cancer,":[283,295],"demonstrating":[284],"a":[285],"favorable":[286],"profile":[288],"alongside":[289],"manageable":[290],"concerns.":[292],"Keywords:":[293],"T-DM1,":[296],"pyrotinib,":[297],"capecitabine,":[298],"HER2":[299]},"counts_by_year":[{"year":2025,"cited_by_count":1}],"updated_date":"2026-10-16T09:59:22.235173","created_date":"2025-10-10T00:00:00"}